Abstract 1277P
Background
There is an unmet need for post-surgical therapeutic options in early-stage NSCLC patients. PARP inhibitors (PARPi) have shown efficacy in cancer patients harboring germline or/and somatic BRCA1/BRCA2 mutations and homologous recombination deficiency (HRD). Patient selection for targeted treatment is of crucial importance. Thus, the assessment of HRD status in patients with early-stage NSCLC may pave the way for the use of PARPi in an adjuvant setting.
Methods
Tumor specimens and peripheral blood samples were analyzed for somatic and germ-line mutations with a customized panel of 58 genes. To assess HRD status the genomic scar score (GSS) was calculated using the AmoyDx® HRD Focus Panel or AmoyDx® HRD Complete Panel. The effect of PARP inhibition on tumour growth was assessed in patient-derived xenografts, where RAD51 foci were quantified by immunofluorescence.
Results
Six of 85 patients (59 men/26 women) with operable NSCLC, carried germline mutations in BRCA1 (n=1), BRCA2 (n=1), ATM (n=3), and PALB2 (n=1) genes. Pathogenic somatic mutations were detected in BRCA1 (n=8), BRCA2 (n=9), ATM (n=8), PALB2 (n=3), CHEK1 (n=3), CHEK2 (n=6), RAD50 (n=5) and TP53 (n=49) genes. Based on GSS, 25 (29.4%) patients were characterized as HRD and at least one somatic HRR mutated gene was observed in 15 (57.7%) of them [BRCA1 (n=4), BRCA2 (n=4), ATM (n=3), PALB2 (n=2), CHEK2 (n=1) ]. Preliminary functional experiments in HRP (HR proficient, n=5) and HRD (n=4) PDX and organoids (n=3 and n=3 for HRD and HRP respectively) indicate that HRD tumors present low RAD51 foci count (p=0.03 after damage induction) and favorable response to Olaparib and CDDP.
Conclusions
These data suggest that homologous recombination may be deficient in a substantial proportion of early-stage NSCLC patients, supporting the potential use of PARPi in HRD patients in the adjuvant or maintenance setting.
Clinical trial identification
N/A
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
Amoy Diagnostics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1301P - A prognostic clinical and circulating biomarker model to identify futile chemo-radiotherapy (CRT) in stage III NSCLC
Presenter: Rianne Vaes
Session: Poster session 04
1302P - Treatment outcomes and safety of durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in Thai populations: A real-world, multi-center observational study
Presenter: Piyada Sitthideatphaiboon
Session: Poster session 04
1303P - Immune-modulating effects on tumor draining lymph nodes following neoadjuvant chemoradiotherapy combined with immunotherapy in patients with T3-4N0-1 NSCLC
Presenter: Ezgi Ulas
Session: Poster session 04
1304P - A structured multidisciplinary approach for diagnosing immune-related pneumonitis in patients undergoing adjuvant durvalumab for stage III non-small cell lung cancer
Presenter: Illaa Smesseim
Session: Poster session 04
1305P - Importance of the resected lung tumor specimen in patients with locally advanced and metastatic non-small cell lung cancer undergoing prior targeted therapy
Presenter: Jeong Uk Lim
Session: Poster session 04
1307P - The Biocartis Idylla GeneFusion Assay (RUO) for lung cancer testing: The experience of testing over 5000 tumours in routine practice
Presenter: Lee Robertson
Session: Poster session 04
1308P - Diameter threshold for lung nodules at low-dose CT screening: Chinese population screening experience
Presenter: YE WENJUN
Session: Poster session 04
1309P - Immune exhaustion in tumor-free lymph nodes of non-small cell lung cancer (NSCLC) patients is associated with performance status and survival
Presenter: Laura Sellmer
Session: Poster session 04
1310P - Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes
Presenter: Xiwen Liu
Session: Poster session 04
1311P - Understanding the basis for intrinsic resistance to KRASG12C inhibitors
Presenter: Alba Santos Ramos
Session: Poster session 04